A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS) Clinical Trial

Official title:

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02944955
• Other study ID #: BLI-1301-01
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 1, 2025
• Est. completion date: June 30, 2026

Study information

• Verified date: July 2023
• Source: BioLite, Inc.
• Contact: Hsien-Ming Wu, M.S.
• Phone: +886-3-6685386
• Email: sonnywu[@]bioliteinc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: June 30, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Age 20 or older, able to sign informed consent, understand and comply with protocol requirements and instructions.
• Body weight between 30 to 120 kg
• International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) by World Health Organization (WHO) or Chronic Myelomonocytic Leukemia (CMML) patients.
• Not previously treated with MDS and CMML therapy and require treatment with azacitidine* for the first time at 75 mg/m2 subcutaneously or intravenously, daily for 7 days (7 nonconsecutive day of 6-1-1 or 5-2-2 treatment schedule is acceptable in which the drug is administered Monday-Saturday and then Monday of the following week for a 6-1-1 schedule, and in which the drug is administered Monday-Friday and then Monday-Tuesday of the following week for 5-2-2 schedule) per cycle. Treatment of the study drug, BLEX 404 Oral Liquid will begin at the same time receiving the first dose of azacitidine in this study.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3.
• Adequate baseline organ function defined by the criteria below: total bilirubin = 1.5x the upper limit of normal (ULN) except for Gilbert's syndrome or indirect hyperbilirubinemia due to hemolysis; ALT = 2.5x ULN; AST = 2.5x ULN; creatinine clearance = 60 mL/min/1.73 m2.
• Women must be either of non-child bearing potential, or women with child-bearing potential and men with reproductive potential and a female partner of childbearing potential must either have had a prior vasectomy or agree to use effective contraception from time of Screening Visit until the Follow-Up Visit.

Exclusion Criteria:

• Historical allergic events caused by mushroom.
• Previous treatment with hypomethylating agent or known immediate or delayed hypersensitivity reaction to drugs chemically related to azacitidine that contraindicates the subjects' participation.
• Patients with active infections or require treatments with immunosuppressive drugs at screening visit. However, patients require ongoing treatments with corticosteroids may be recruited.
• Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of BLEX 404 Oral Liquid.
• Any serious and/or unstable pre-existing medical condition (including any advanced malignancy other than the disease under study), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study procedures.
• Any clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying hematologic disorder.
• Active and uncontrolled infections of the following: hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV) infection. However, HBV and HCV carriers with viral load test of "not detected" or "negative" results may be recruited in this study.
• Lactating female and women with a positive serum or urine pregnancy test at screening assessments.
• (For Part II Interventional Study subjects only) No indication, in the opinion of the treating physician, for antibiotic prophylaxis within 2 weeks prior to study treatment.

Related Conditions & MeSH terms

• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndrome (MDS)
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• BLEX 404 Oral Liquid
BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II). Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
BioLite, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part I: Recommended dose level (RDL) of BLEX 404 Oral Liquid	RDL is defined by BLEX 404 Oral Liquid-related prohibited toxicity in subjects undergoing 2 cycles of azacitidine treatment. When one of the stopping criteria is met during the study treatment period, RDL will be set at the lower dose level.	8 weeks (2 cycles of azacitidine)
Primary	Part II: Incidence of infections	Number of subjects experience infection events and inpatient hospitalization due to infections.	24 weeks (6 cycles of azacitidine)
Secondary	Part I: (A) Number of subjects experience infections events and inpatient hospitalization due to infections		8 weeks (2 cycles of azacitidine)
Secondary	Part I: (B) Treatments and duration of each infections		8 weeks (2 cycles of azacitidine)
Secondary	Part I: (C) Complete remission (CR) or partial remission (PR) of bone marrow, peripheral blood, cytogenetic response (defined by 2006 IWG Criteria)	Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 2 cycles of azacitidine.	8 weeks (2 cycles of azacitidine)
Secondary	Part I: (D) Hematological improvement of erythroid (hemoglobin and RBC-transfusion independence), neutrophil (Absolute Neutrophil Count), and platelet (platelet count) response (defined by 2006 IWG Criteria)	Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 2 cycles of azacitidine.	8 weeks (2 cycles of azacitidine)
Secondary	Part I: (E) Frequency and requirement of red blood cell transfusion (defined by 2006 IWG Criteria)	Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 2 cycles of azacitidine.	8 weeks (2 cycles of azacitidine)
Secondary	Part I: (F) Disease Progression (defined by 2006 IWG Criteria)	Disease progression of bone marrow, erythroid (hemoglobin and RBC-transfusion independence), and platelet (platelet count) in subjects undergone BLEX 404 Oral Liquid treatment in combination with 2 cycles of azacitidine.	8 weeks (2 cycles of azacitidine)
Secondary	Part II: (A) Time-to-first infection		24 weeks (6 cycles of azacitidine)
Secondary	Part II: (B) Duration (days) of each infection event		24 weeks (6 cycles of azacitidine)
Secondary	Part II: (C) Number of infections requiring supportive care or antimicrobial agents		24 weeks (6 cycles of azacitidine)
Secondary	Part II: (D) Duration (days) of treatments for infections		24 weeks (6 cycles of azacitidine)
Secondary	Part II: (E) Complete remission (CR) or partial remission (PR) of bone marrow, peripheral blood, cytogenetic response (defined by 2006 IWG Criteria)	Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 6 cycles of azacitidine.	24 weeks (6 cycles of azacitidine)
Secondary	Part II: (F) Hematological improvement of erythroid (hemoglobin and RBC-transfusion independence), neutrophil (Absolute Neutrophil Count), and platelet (platelet count) response (defined by 2006 IWG Criteria)	Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 6 cycles of azacitidine.	24 weeks (6 cycles of azacitidine)
Secondary	Part II: (G) Frequency and requirement of red blood cell transfusion (defined by 2006 IWG Criteria)	Hematological Response in subjects undergone BLEX 404 Oral Liquid in combination with 6 cycles of azacitidine.	24 weeks (6 cycles of azacitidine)
Secondary	Part II: (H) Disease Progression (defined by 2006 IWG Criteria)	Disease progression of bone marrow, erythroid (hemoglobin and RBC-transfusion independence), and platelet (platelet count) in subjects undergone BLEX 404 Oral Liquid treatment in combination with 2 cycles of azacitidine.	24 weeks (6 cycles of azacitidine)
Secondary	Part II: (I) Six-month overall survival rate (defined by 2006 IWG Criteria)	defined as time from beginning of treatment till death from any cause occurs or last follow-up.	24 weeks (6 cycles of azacitidine)
Secondary	Part II: (J) Six-month progression-free survival (defined by 2006 IWG Criteria)	defined as time from beginning of treatment till disease progression, death from MDS or CMML, or last follow-up.	24 weeks (6 cycles of azacitidine)
Secondary	Part II: (K) Immune Response	Neutrophil and monocyte function by respiratory burst assay	24 weeks (6 cycles of azacitidine)